NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-115-2013-0-DE-06 Encircling Implant Delivery System And Methods DE EP 14735030.0 Issued
NHLBI E-115-2013-0-FR-07 Encircling Implant Delivery System And Methods FR EP 14735030.0 Issued
NHLBI E-115-2013-0-PCT-02 Encircling Implant Delivery System And Methods PCT PCT PCT/US2014/040716 Expired
NCATS E-234-2012-0-EA-11 PAK Inhibitors For the Treatment of Fragile X Syndrome EA National Stage 201490925 Pending
NINDS E-043-2012-0-US-03 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging US National Stage 14/362,354 9607392 Issued PDF
NICHD E-274-2000-0-US-05 Vibrio Cholerae 0139 Conjugate Vaccines US DIV 14/293,745 9173932 Abandoned PDF
NCI E-058-2015-1-JP-04 MATERIALS AND METHODS RELATED TO NSAID CHEMOPREVENTION IN COLORECTAL CANCER JP National Stage 2014-544988 Abandoned
NCATS E-234-2012-0-VN-26 PAK Inhibitors For the Treatment of Fragile X Syndrome VN National Stage 1-2014-01801 Pending
NCI E-042-2014-0-US-01 Chimeric Antigen Receptors Targeting CD-19 US 62/006,313 Abandoned
NIAID E-148-2009-2-US-03 Use Of Ixolaris, A Tissue Factor Inhibitor, For Inhibiting Angiogenesis US DIV 14/292,232 9272023 Issued PDF
NCI E-058-2015-1-US-07 THE MECHANISM OF NSAID CHEMOPREVENTION IN COLORECTAL CANCER US National Stage 14/361,940 Abandoned
NCI E-181-2012-0-US-04 TUMOR-SPECIFIC GM-CSF CYTOKINE RESPONSE AS PREDICTOR OF CANCER VACCINE EFFECTIVENESS US National Stage 14/362,093 Abandoned
NCATS E-234-2012-0-KR-17 PAK Inhibitors For the Treatment of Fragile X Syndrome KR National Stage 10-2014-7014685 Pending
NCI E-508-2013-1-US-01 Method of Treating Or Preventing Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease US 62/004,436 Abandoned
NCI E-176-2014-0-US-01 Anti-Human Papillomavirus-16 E7 T Cell Receptors US 62/004,335 Abandoned
NCI E-104-2014-0-US-01 Method of Treating Fumarate Hydratase-Deficient Kidney Cancer US 62/003,319 Abandoned
NIAID E-066-2014-0-US-01 Stabilized Influenza Hemagglutinin Stem Region Trimers & Uses Thereof US 62/003,471 Abandoned
NCATS E-234-2012-0-MA-18 PAK Inhibitors For the Treatment of Fragile X Syndrome MA National Stage 37064 Pending
NCI E-090-2000-1-US-13 NOVEL MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN, NY ESO-1 US DIV 14/284,971 9447144 Expired PDF
NIBIB E-137-2015-0-US-01 Photosensitizer-Loaded Gold Vesicles With Strong Plasmonic Coupling Effect For Imaging-Guided Photothermal/Photodynamic Therapy US 62/001,977 Abandoned
NCI E-173-2012-2-US-03 USE OF PDL1 EXPRESSING CELLS TO CONVERT T CELLS INTO REGULATORY T CELLS US National Stage 14/359,764 9644179 Issued PDF
NCI E-340-2007-0-AU-17 MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PRONOSIS AND TREATMENT OF PROSTATE RELATED DISORDERS AU DIV 2014202735 Abandoned
NINR E-349-2013-2-PCT-01 Detection And Treatment Of Irritable Bowel Syndrome PCT PCT COMB PCT/US2014/038638 Expired
NICHD E-259-2014-0-US-01 Method For Computing T1-T2 Relaxation Spectra Using A Vastly Reduced Amount Of MR Data US 62/000,316 Abandoned
NHLBI E-076-2014-0-US-01 Small Molecule Activators And Inhibitors Of Lecithin:CholesterolAcyltransferase US 61/994,987 Abandoned
NCI E-039-2012-2-US-05 Auto-recognizing Therapeutic RNA/DNA Chimeric Nanoparticles (NP)58942 US National Stage 14/358,942 9631192 Issued PDF
NCI E-038-2012-2-US-06 Therapeutic RNA Switches Compositions And Methods Of Use US National Stage 14/359,019 Abandoned
NIBIB E-167-2014-0-US-01 Glucose Oxidase-Catalyzed Growth of Gold Nanoparticles Enables Quantitative Detection of Attomolar Cancer Biomarkers US 61/994,622 Abandoned
NCI E-257-2009-1-NZ-09 Use Of IL-15 To Increase Thymic Output and to Treat Lymphopenia NZ DIV 625008 Abandoned
NIAID E-070-2014-0-US-01 TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER US 61/993,637 Abandoned
NIDCR E-032-2013-0-US-03 METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS US National Stage 14/358,077 Abandoned
NCI E-169-2014-0-US-01 Method of Treating Cancer Using Olaparib and Cediranib US 61/996,683 Abandoned
CC E-195-2015-0-US-01 System And Method For CT Image Synthesis From MRI Using Generative Sub-image Synthesis US 61/996,653 Abandoned
NCI E-266-2011-0-CN-08 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage CN National Stage 201280055972.X Abandoned
NCI E-005-2011-0-US-02 Soluble CD27 (sCD27) And Use Thereof US ORD 14/276,713 9725494 Abandoned PDF
NCI E-093-2013-2-PCT-01 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase PCT PCT PCT/US2014/037905 Expired
NCI E-093-2013-2-CN-04 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase CN National Stage 201480039611.5 Abandoned
NCI E-093-2013-2-EP-05 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase EP National Stage 14728395.6 Pending
NCI E-093-2013-2-JP-07 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase JP National Stage 2016-514045 Abandoned
NCI E-093-2013-2-CA-03 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase CA National Stage 2912064 Abandoned
NCI E-093-2013-2-ZA-09 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase ZA National Stage 2015/08408 Abandoned
NCI E-093-2013-2-BR-02 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase BR National Stage BR1120150287603 Abandoned
NCI E-093-2013-2-IN-06 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase IN National Stage 3937/KOLNP/2015 Abandoned
NCI E-025-2009-0-NZ-17 Ratio Based Biomarkers And Methods of Use Thereof NZ DIV 624816 Issued
NCI E-203-2000-0-US-13 Biologically Active Macrolides, Compositions, and Uses Thereof US CON 14/275,336 9139595 Abandoned PDF
NINDS E-121-2014-0-US-01 Miniature Serial Sectioning Microtome For Block-face Imaging US 61/991,929 Expired
NCI E-008-2014-1-US-01 Thymic Stromal Lymphopoietin Receptor-Specific Chimeric Antigen Receptors and Methods Using Same US 61/991,697 Abandoned
NCATS E-234-2012-0-ID-14 PAK Inhibitors For the Treatment of Fragile X Syndrome ID National Stage P-00201402804 Abandoned
NIAID E-136-2013-0-AR-03 Single-Domain VHH Antiobodies Directed To Norovirus GI.1 And GII.4 And Their Use AR ORD 20140101882 Abandoned
NIAID E-281-2011-0-US-03 SYNTHETIC CATALASE/SUPEROXIDE DISMUTASE MIMETICS AND METHODS FOR TREATING VIRAL INFECTIONS US National Stage 14/357,556 10683316 Issued PDF